Loading clinical trials...
Loading clinical trials...
To evaluate the clinical efficacy and safety in patients with Laryngopharyngitis or Tonsillitis or Acute Bacterial Rhinosinusitis receiving a dose of 2 g of azithromycin in the SR formulation.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Pfizer
NCT07552779 · Coronavirus Disease 2019, Coronavirus Disease 2019 (COVID-19), and more
NCT07041671 · URTI - Viral Upper Respiratory Tract Infection
NCT07154992 · Upper Respiratory Tract Infection, Prevention
NCT06271655 · Acute Respiratory Infection, Viral Infection, and more
NCT02484417 · Upper Respiratory Tract Infection
Pfizer Investigational Site
Gobō, Wakayama
Pfizer Investigational Site
Hashimoto, Wakayama
Pfizer Investigational Site
Shinjo-cho, Tanabe, Wakayama
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions